Diabetes mellitus (DM) precipitously increases the number of non-traumatic lower extremity amputations (LEAs) 1, 2 and re-amputations. 3 This increase is mediated via 3 mechanisms. First, hyperglycemia contributes to delayed and impaired wound healing. 4 Second, it is a major risk factor for diabetic peripheral neuropathy 5 and peripheral arterial disease. 6 Third, it is a risk factor for diabetic foot infections. 7, 8 Accordingly, stringent glycemic control should be very useful toward reducing LEAs, and the relationship of glycated hemoglobin (HbA 1c ) with the incidence of LEAs is of particular interest.
In this issue of the journal, a meta-analysis including 16 studies from various countries has looked at the role of HbA 1c as a risk factor for LEAs in DM. 9 A significant difference in HbA 1c was found between diabetic patients with and those without LEAs (mean difference = 1.110; 95% confidence interval [CI] = 0.510-1.709; P = .008). 9 Furthermore, there was a significant (P = .000) association between HbA 1c and risk of LEAs. For every 1% increase in the former, the odds ratio of the latter was 1.229 (95% CI = 1.169-1.292). 9 Of note, patients with HbA 1c > 9% exhibited a particularly high LEA risk.
This meta-analysis adds to the accumulating data on hyperglycemia as an independent risk factor for LEAs in DM. 10, 11 So far, relevant information has been, to some extent, limited by the small numbers and diverse patient characteristics including ethnicity and severity of foot pathology. [9] [10] [11] Therefore, the new solid evidence is very useful.
The strengths of the present meta-analysis are the large number of patients included, the ability to show absence of publication bias, as well as the use of various models to quantify the risk conferred by high HbA 1c . 9 Its main limitation is the failure to distinguish between major and minor LEAs. Two further limitations include the absence of serial HbA 1c measurements providing information on long-term glycemic control and the inability to examine LEAs separately in type 1 and type 2 DM. 9 The implication of this meta-analysis is that improved glycemic control is important in reducing LEAs in DM. In practice, optimized metabolic control should be more vigorously attained in the setting of highly organized multidisciplinary diabetic foot clinics. 12, 13 Plasma glucose needs to be appropriately reduced, while an efficacious antidiabetic regimen for use at home following appointment and/or discharge from hospital with a meticulous patient follow-up plan are necessary to ensure that strict glycemic control is indeed maintained. Such measures should be incorporated in the overall treatment strategy, along with revascularization, infection control, orthotic devices, and adjunctive modalities or innovations. [13] [14] [15] Perhaps more important, better glycemic control is the utmost goal for all health care settings, including diabetologists but also general practitioners, contributing to the future prevention of LEAs. 16 In conclusion, the recent meta-analysis has provided robust evidence on the role of high HbA 1c as a risk factor for LEAs in DM. The risk of LEAs progressively increases with rising HbA 1c . 9 Hence, optimized glycemic control is confirmed as a major therapeutic target for patients with DM, in order to reduce amputations. This priority of glycemic control should now be pursued even more broadly and zealously, because reducing blood sugar may contribute to the "sweetest" success. 17 
